Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib versus placebo as maintenance therapy for recurrent ovarian cancer
CTR20190294Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hengrui Therapeutics. Started Apr 2019; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20190294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190294.